Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Europe

Italy Leads European Push Into Conditional Reimbursement

  • News
  • Andrew Shelton

Executive Summary

Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.

You may also be interested in...



EMA Director-Nominee Guido Rasi Brings Track Record For Repairing Regulatory Agency Reputation

Rasi leads the Italian Medicines Agency, an agency also known for conditional reimbursement agreements.

EMA Director-Nominee Guido Rasi Brings Track Record For Repairing Regulatory Agency Reputation

Rasi leads the Italian Medicines Agency, an agency also known for conditional reimbursement agreements.

Celgene Ups Vidaza Discount To Gain Positive NICE Recommendation

U.K. cost-watchdog NICE recommends reimbursement for Celgene's Vidaza after the company offers a steeper discount.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical Europe
UsernamePublicRestriction

Register

PS053353

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By